| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Barbara Ensoli | Q21255143 |
| Antonella Caputo | Q56810196 | ||
| P2093 | author name string | Riccardo Gavioli | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 357-376 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Current HIV Research | Q5195049 |
| P1476 | title | Recent advances in the development of HIV-1 Tat-based vaccines | |
| P478 | volume | 2 |
| Q44280840 | A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q35024266 | AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens |
| Q42412643 | Amino acid sequence divergence of Tat protein (exon1) of subtype B and C HIV-1 strains: Does it have implications for vaccine development? |
| Q39797438 | Antigen expression kinetics and immune responses of mice immunized with noninfectious simian-human immunodeficiency virus DNA |
| Q61641053 | Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin |
| Q46860089 | Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins |
| Q57373962 | DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination |
| Q40112826 | Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity. |
| Q43880475 | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant |
| Q61641083 | Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag |
| Q45413779 | Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses |
| Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q36786660 | Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. |
| Q47738688 | Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration |
| Q39708894 | Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. |
| Q36920457 | Nanoparticles in modern medicine: state of the art and future challenges |
| Q93627880 | Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study |
| Q60243630 | Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes |
| Q47776137 | Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice |
| Q36758574 | Problems and emerging approaches in HIV/AIDS vaccine development |
Search more.